ArticleFrontiers in public health2025
Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Sustainable Development Goal 3.2 urges nations to reduce neonatal mortality rates to no more than 12 deaths per 1,000 live births by 2030. Neonatal encephalopathy (NE), the third leading cause of under-five mortality, significantly impacts global neonatal death rates and long-term health. A comprehensive assessment is essential to inform public health strategies. This study aims to analyze the burden of Neonatal Encephalopathy on global, regional, and national levels. Methods: Data on the age-standardized mortality rate (ASMR) and age-standardized incidence rates (ASIR) for NE from 1990 to 2021 were obtained from the Global Burden of Disease Study (GBD) 2021. To evaluate the changes in ASIR and ASMR associated with the burden of NE, estimated annual percentage changes (EAPC) and overall percentage changes were calculated. Furthermore, the relationship between disease burden and the Sociodemographic Index (SDI) was analyzed, along with predictions generated using autoregressive integrated moving average (ARIMA) model. Results: The global burden of NE has significantly declined over the past three decades. Between 1990 and 2021, the global ASIR decreased from 20.22 to 17.16, while the number of cases fell from 1,295,891.1 to 1,061,448.15, reflecting an 18.09% reduction. Similarly, the global ASMR declined from 13.81 in 1990 to 9.75 in 2021, with deaths decreasing from 883,082.06 to 603,605.62, representing a 31.65% reduction. Projections based on ARIMA models indicate that from 2022 to 2030, the global ASIR is expected to decline from 17.06 to 16.36, and the ASMR is projected to decrease from 9.55 to 7.98, suggesting a continued reduction in the burden of NE. Conclusion: This study illustrates the global progress made in reducing neonatal encephalopathy from 1990 to 2021; however, significant disparities persist. Targeted interventions are crucial to address these inequities and to achieve Sustainable Development Goal 3.2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.